Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stratec SESTU:SBS 73 3-1 Month Momentum % is 15.55% as of Sep. 22, 2026. GuruFocus rates STU:SBS with a GF Score™ of 73/100 and a GF Value™ of €27.73 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 849 Medical Devices & Instruments companies, Stratec SE ranks better than 84.45% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-22), Stratec SE's 3-1 Month Momentum % is 15.55%.
The industry rank for Stratec SE's 3-1 Month Momentum % or its related term are showing as below:
STU:SBS's 3-1 Month Momentum % is ranked better than 84.45% of 849
companies
in the Medical Devices & Instruments industry
Industry Median: 0.51
vs STU:SBS: 15.55
Stratec SE (STU:SBS) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Stratec SE 3-1 Month Momentum % Related Terms
STU:SBS vs ABT, SYK, MDT: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, Stratec SE's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stratec SE 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stratec SE's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Stratec SE's 3-1 Month Momentum % falls into.
Stratec SE (STU:SBS) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stratec SE (STU:SBS) has a 3-1 Month Momentum % of 15.55% as of Sep. 22, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Stratec SE and its competitors. According to the industry distribution chart, Stratec SE ranks #132 out of 849 companies in the Medical Devices & Instruments industry, placing it in the top 15.5%.
Is Stratec SE's 3-1 Month Momentum % too high?
Stratec SE's current 3-1 Month Momentum % is 15.55%. The Medical Devices & Instruments industry median 3-1 Month Momentum % is 0.51. Stratec SE's value of 15.55% is 2949% above this industry median. Based on the distribution chart, Stratec SE ranks #132 out of 849 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Stratec SE has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Stratec SE's 3-1 Month Momentum % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Stratec SE ranks #132 out of 849 companies for 3-1 Month Momentum %. This places Stratec SE in the top 16% of its industry — outperforming the majority of peers. The industry median 3-1 Month Momentum % is 0.51. Stratec SE's value of 15.55% is 2949% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
The median 3-1 Month Momentum % among Medical Devices & Instruments companies is 0.51, based on 849 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stratec SE's current 3-1 Month Momentum % of 15.55% is 2949% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Stratec SE and its competitors. For the Medical Devices & Instruments industry, the median 3-1 Month Momentum % is 0.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stratec SE's current 3-1 Month Momentum % is 15.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stratec SE stock overvalued right now?
Based on GuruFocus' analysis, Stratec SE (STU:SBS) is currently considered Modestly Undervalued. The stock's GF Value™ is €27.73, compared to a current price of €22.70 — trading 18.1% below its estimated fair value. The current 3-1 Month Momentum % is 15.55% and 2949% above the Medical Devices & Instruments industry median of 0.51. Stratec SE's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Stratec SE (STU:SBS), the current 3-1 Month Momentum % is 15.55% as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stratec SE (STU:SBS) Overvalued in 2026?
Based on GuruFocus' analysis, Stratec SE stock appears to be undervalued.
The current stock price of €22.70 is trading 18.1% below its estimated GF Value™ of €27.73.
GuruFocus considers Stratec SE to be Modestly Undervalued.
Key valuation signals for STU:SBS:
3-1 Month Momentum %: 15.55%
GF Value™: €27.73 vs. price of €22.70 (18.1% below fair value)
Industry Position: 2949% above the Medical Devices & Instruments median (#132 of 849)
No single metric tells the full story. See the STU:SBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stratec SE is a German company that develops and manufactures automated analyzer systems and instrumentation for the in-vitro diagnostics and life sciences industries. Operating primarily as an original equipment manufacturer (OEM), it supplies complete systems, modules, software, and consumables to diagnostics and life science companies, which market these platforms under their own brands, often alongside their proprietary reagents. Its portfolio covers sample preparation, detection, and laboratory automation technologies used in regulated clinical and research settings. Customers include major diagnostics corporations and emerging assay developers, mainly across Europe, North America, and Asia. Revenue is generated through development projects, serial hardware production, and recurring consumable and service sales tied to installed instrument bases. The company is headquartered in Birkenfeld, Germany, and is listed on the Frankfurt Stock Exchange.
73GF Score
Get the complete analysis for STU:SBS
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:SBS has been successfully added to your 
